Pfizer To Buy Trillium For $2.26bn In A Hematology Pipeline Play

 
• By Jessica Merrill

Pfizer will gain two clinical-stage immuno-oncology assets targeting the SRRPα-CD47 axis that it hopes could reach the market in the 2025-2030 timeframe.

shopping cart
Pfizer is shopping for new clinical-stage assets • Source: Alamy

More from Deals

More from Business